glp 1 agonist side effects GLP-1 Effects: A Complete Guide to What You Can Expect Adverse Effects of GLP-1 Receptor

Popularity spiked dramatically following Wegovy's approval, with prescriptions doubling in 2022 and again in 2023

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, et al

Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold

Three exclusive sections Patient Access Economics, Biosimilar Entry Framework, and Population Health ROI Framework provide unique intelligence not available in comparable GLP-1 market reports